Healthcare / Medical DistributionSES
$0.33
-0.01 (-1.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $4.4M · quality 58.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$100M
P/E
16.3x
↓EV/EBITDA
7.3x
↓ROE
8.3%
↑Gross Margin
40.7%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.0%
FCF CAGR
+4.0%
FCF margin
9.9%
FCF / Net income
2.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $177.4M · net income $5.8M · FCF $17.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $177.4M | $177.4M | $195.4M | $170.6M | $162.3M |
| Net Income | $5.8M | $5.8M | $10.2M | $8.6M | $11.4M |
| EBITDA | $11.4M | $11.4M | $16.6M | $13.6M | $17.3M |
| EPS | — | — | 0.03 | 0.03 | 0.04 |
| Gross Margin | 40.7% | 40.7% | 35.6% | 36.3% | 38.7% |
| Operating Margin | 8.7% | 8.7% | 7.6% | 7.1% | 9.5% |
| Net Margin | 3.3% | 3.3% | 5.2% | 5.0% | 7.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.20 | 0.11 | 0.08 |
| Current Ratio | 2.03 | 2.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $17.5M | $17.5M | $-3.1M | $4.4M | $15.6M |
| Returns | |||||
| ROE | 8.3% | 8.3% | 14.4% | 13.6% | 16.4% |
| Valuation | |||||
| P/E | 16.25 | 16.25 | 8.80 | 10.65 | 8.88 |
| EV/EBITDA | 7.28 | 7.28 | 4.85 | 5.48 | 4.06 |
| P/B | 1.43 | 1.43 | 1.27 | 1.45 | 1.46 |
| Growth & Yield | |||||
| Revenue Growth | -9.2% | -9.2% | 14.6% | 5.1% | — |
| EPS Growth | — | — | 17.0% | -24.3% | — |
| Dividend Yield | 4.6% | 4.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.03 → n/d
Residual
+6.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.